Intestinal mucosal dysfunction and infection during remission-induction therapy for acute myeloid leukaemia
Authors:
- 2 November 2006
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 20 (12) , 2087-2092
Abstract
Intestinal barrier function was prospectively examined in the course of a clinical trial evaluating the efficacy and safety of lisofylline for reducing cytotoxic therapy-induced intestinal epithelial damage-related infectious morbidity in patients receiving standard remission-induction therapy for acute myeloid leukaemia. The absorption and permeation of oral D-Xylose, lactulose and mannitol were measured weekly from baseline until marrow recovery in adult recipients of idarubicin plus cytarabine for untreated acute myeloid leukaemia. These studies were correlated with non-haematologic chemotherapy-related toxicities reflecting mucosal damage, including nausea, vomiting, stomatitis, diarrhoea, abdominal pain and systemic infection. D-xylose absorption decreased and lactulose:mannitol ratio reflecting intestinal permeability increased from baseline until the second and third week after the beginning of the treatment followed by recovery. These measures correlated with infection rates, nausea, vomiting, diarrhoea and increased blood product utilization. Lisofylline was associated with increased intestinal permeability, nausea, vomiting and infection-related morbidity despite a reduction in the duration of neutropaenia. These surrogates of intestinal barrier function correlated well with clinically important outcomes despite the failure to demonstrate reduced morbidity with lisofylline and represent useful objective outcome measurements for future clinical trials of products for the amelioration of the effects of cytotoxic therapy on the intestinal mucosa.Keywords
This publication has 34 references indexed in Scilit:
- Prospective evaluation of gut mucosal barrier injury following various myeloablative regimens for haematopoietic stem cell transplantBone Marrow Transplantation, 2005
- Perspectives on cancer therapy-induced mucosal injuryCancer, 2004
- Pathobiology of mucositisSeminars in Oncology Nursing, 2004
- Oral and intestinal mucositis — causes and possible treatmentsAlimentary Pharmacology & Therapeutics, 2003
- The burdens of cancer therapyCancer, 2003
- Can anything be done about oral mucositis?Annals of Oncology, 2003
- Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatmentBone Marrow Transplantation, 2003
- Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescueBritish Journal of Haematology, 2000
- Analysis of Factors That Correlate With Mucositis in Recipients of Autologous and Allogeneic Stem-Cell TransplantsJournal of Clinical Oncology, 1999
- Acute myeloid leukemia in manitobaCancer, 1994